

## Considerations for Clinical Implementation of Immunotherapy in Veterinary Oncology On Demand

Premier Sponsor



Agenda		
Session Duration	Topic	Presenter(s)
60 minutes	<p>Past Present Future of Immunotherapy</p> <ul style="list-style-type: none"> <li>• Be more fluent in cancer immunotherapy principles.</li> <li>• Recognize the various cancer immunotherapy approaches utilized to date.</li> <li>• Better understand the mechanism of action of various checkpoint inhibitors like Gilvetmab.</li> </ul>	<i>Dr. Philip Bergman</i>
60 minutes	<p>Tuning CARs for Optimal Performance in the Veterinary Space</p> <ul style="list-style-type: none"> <li>• Describe the components of a chimeric antigen receptor (CAR)-T cell, the general concepts of how they are manufactured and their effects in human hematological malignancies and the correlative biomarkers of response that have been identified.</li> <li>• Describe the major biological and logistical barriers to effective CAR-T cell therapy for liquid and solid tumors in human and veterinary patients.</li> <li>• Describe 3 different strategies being used to overcome the limitations of CAR-engineered cells in the treatment of liquid and solid tumors.</li> </ul>	<i>Dr. Nicola Mason</i>
60 minutes	<p>How Immunotherapy Has Altered the Paradigm in Human Oncology</p> <ul style="list-style-type: none"> <li>• Identify agents currently active in various diseases with respective toxicities.</li> <li>• Understand the rationale for combination therapies and checkpoint blockade.</li> <li>• Understand the data to date for combination checkpoint blockade.</li> </ul>	<i>Dr. Jedd Wolchok</i>

## Considerations for Clinical Implementation of Immunotherapy in Veterinary Oncology On Demand

Premier Sponsor



Agenda (cont.)		
Session Duration	Topic	Presenter(s)
60 minutes	<p>Panel Discussion</p> <ul style="list-style-type: none"> <li>• Compare how immunotherapy strategies, including checkpoint inhibitors and CAR-T cells, are being developed and applied in both human and veterinary oncology.</li> <li>• Evaluate current limitations and opportunities in translating human immunotherapy advances to veterinary patients.</li> <li>• Discuss the future directions of cancer immunotherapy, including novel targets, combination strategies, and anticipated challenges in clinical implementation.</li> </ul>	<p><i>Dr. Philip Bergman</i> <i>Dr. Nicola Mason</i> <i>Dr. Jedd Wolchok</i></p> <p><i>Moderator: Drs. Heather Gardner and Kai Shiu</i></p>
60 minutes	<p>Exploring Immune-Oncology Treatment Strategies for Canine Lymphoma</p> <ul style="list-style-type: none"> <li>• Become familiar with targets for therapeutic intervention in T and B cell lymphomas in dogs.</li> <li>• Understand how different immunotherapeutic strategies can be combined with small molecule inhibitors/chemotherapeutics to treat lymphoma in dogs.</li> <li>• Evaluate biomarkers that may be useful for predicting treatment responsiveness.</li> </ul>	<p><i>Dr. Cheryl London</i> <i>Dr. Jillian Richmond</i></p>
60 minutes	<p>Immune Checkpoint Inhibitors: State of the Art and Pathways to Future Veterinary Applications</p> <ul style="list-style-type: none"> <li>• Understand the mechanism of action, potential adverse events and management, and practical application of ICIs.</li> <li>• Relate examples of ICI utility observed thus far during the short history of ICI availability in companion species.</li> <li>• Understand possible strategies currently being investigated in veterinary patients to increase the likelihood of ICI efficacy through combinations with other treatment modalities (e.g., radiation therapy, surgery, other Immunotherapeutics).</li> </ul>	<p><i>Dr. David Vail</i> <i>Dr. Christian Capitini</i></p>

## Considerations for Clinical Implementation of Immunotherapy in Veterinary Oncology On Demand

Premier Sponsor



Agenda (cont.)		
Session Duration	Topic	Presenter(s)
60 minutes	<p>Generation of Tumor Reactive Activated T Cells</p> <ul style="list-style-type: none"> <li>• Be familiar with presentation of peptides in context of MHC I and consequences of low MHC I expression.</li> <li>• Be familiar with the costimulatory signals necessary for T cell activation.</li> <li>• Be familiar with the immune synapse and T cell cytotoxicity.</li> <li>• Understand challenges to fully effective T cell therapy.</li> </ul>	<p><i>Dr. Jeffrey Bryan</i></p>
60 minutes	<p>Panel Discussion</p> <ul style="list-style-type: none"> <li>• Integrate emerging immune-oncology strategies for canine cancers with current clinical and experimental approaches.</li> <li>• Interpret the relevance of molecular targets and biomarkers for optimizing treatment selection and predicting therapeutic response in canine patients.</li> <li>• Analyze paradigm shifts in surgical timing and oncologic decision-making in relation to immune system priming for immunotherapy.</li> <li>• Evaluate the impact of antibiotic use and microbiome modulation on the efficacy of immunotherapeutic interventions.</li> </ul>	<p><i>Dr. Cheryl London Dr. Jillian Richmond Dr. David Vail Dr. Christian Capitini Dr. Jeffrey Bryan</i></p> <p><i>Moderator: Drs. Heather Gardner and Kai Shiu</i></p>